The team led by Woei-Cheang Shyu, Vice Superintendent of the Translational Medicine Research Center at China Medical University Hospital, has successfully developed a gene-modified exosome named EXO-PD-L1-HGF derived from mesenchymal stem cells. This innovative therapy not only actively targets damaged brain areas but also effectively suppresses immune responses triggered by stroke, reduces neuronal cell death, and promotes the proliferation and differentiation of endogenous neural stem cells in the brain.
Current Treatment Challenges: Short Therapeutic Window, Limited Efficacy
Stroke and neurodegenerative diseases often lead to irreversible brain damage, resulting in severe aftereffects such as disability and dementia, which significantly impair patients' quality of life and impose heavy burdens on families and society. The standard treatment for acute ischemic stroke, intravenous thrombolysis with rt-PA, is limited by a short therapeutic window and suboptimal efficacy for large clots. Additionally, while stem cell therapy has the potential to repair damaged tissues and promote neural regeneration, it also poses risks related to cell culture stability, immune rejection, and tumorigenicity.
Precision Targeting and Multifunctionality: EXO-PD-L1-HGF Overcomes Treatment Bottlenecks
The EXO-PD-L1-HGF exosome therapy is a non-cellular therapeutic agent that uses exosomes derived from mesenchymal stem cells as carriers to deliver the PD-L1 and HGF genes into the brain. This therapy offers several key advantages:
Experimental data show that EXO-PD-L1-HGF exosomes not only effectively inhibit apoptosis and inflammation caused by stroke in in vitro studies but also promote the proliferation and differentiation of endogenous neural stem cells, leading to the regeneration and repair of brain tissue. In animal studies, the treatment significantly reduced the area of brain damage, promoted neural stem cell proliferation and differentiation, and improved behavioral outcomes in stroke model mice.
Accelerated Technology Transfer and Clinical Trials Bring New Hope to Stroke Patients
Vice Superintendent Shyu stated that EXO-PD-L1-HGF exosome therapy is not only highly effective, safe, and low in immunogenicity but also easy to produce and administer, making it highly convenient for clinical applications. The team is currently in active discussions with biotech companies for technology transfer and licensing and aims to complete the Chemistry, Manufacturing, and Controls (CMC) processes, toxicity testing, and regulatory consultations within two years. The hope is that this innovative exosome therapy will soon enter clinical trials, offering a new treatment option for stroke patients and helping them regain their health and return to normal life.
Resource (mandarin): 突破血腦屏障！基因修飾外泌體療法精準標靶受損腦區
